Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 56

Results For "Director"

2217 News Found

NTPC, Tata Memorial Centre launch cancer awareness initiative
News | June 03, 2024

NTPC, Tata Memorial Centre launch cancer awareness initiative

The cancer screening and awareness camp will run for four months in the Mira Bhayander Region, benefiting approximately 5,000 police personnel


Cupid receives vendor approval from Godrej Consumer for Supply of Kamasutra condoms
News | June 01, 2024

Cupid receives vendor approval from Godrej Consumer for Supply of Kamasutra condoms

This significant achievement includes an initial order from GCPL valued at a substantial Rs. 2.4 crore


Hyperfine bringing Swoop to India through distribution partnership with Radiosurgery Global
Medical Device | May 30, 2024

Hyperfine bringing Swoop to India through distribution partnership with Radiosurgery Global

Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market


Valent BioSciences opens new addition at Melnik and Shafer Biorational Research Center
News | May 30, 2024

Valent BioSciences opens new addition at Melnik and Shafer Biorational Research Center

Greg was also central to the planning, design, and construction of this facility


Merck to acquire EyeBio for US$ 1.3 billion upfront payment
News | May 30, 2024

Merck to acquire EyeBio for US$ 1.3 billion upfront payment

Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration


Asahi Kasei to acquire Calliditas Therapeutics AB to accelerate growth
News | May 29, 2024

Asahi Kasei to acquire Calliditas Therapeutics AB to accelerate growth

Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas


AstraZeneca India posts FY 2023-24 revenue higher at Rs. 1,330 Cr
News | May 28, 2024

AstraZeneca India posts FY 2023-24 revenue higher at Rs. 1,330 Cr

Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth


Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction
Diagnostic Center | May 27, 2024

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction

Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression